News and Media

2015/12/16 – Further advance for Quantum Genomics in securing animal health partnership for heart failure treatment

16 December 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that it has received a letter of intent from its animal health partner. The purpose of this letter of intent […]

2015/11/25 – Quantum Genomics’ Scientific Advisory Board recommends next multicentric clinical trials in Europe and United States

25 November 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has just met in Paris. At that meeting, the Advisory Board reviewed the various investigations under way and recommended future development […]

2015/10/15 – 2015 Half-year results – Update on latest developments

15 October 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces announces its financial results for the first half of the year, ended 30 June 2015 and events after the reporting […]

2015/10/06 – Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure

6 October 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that the Monitoring Board for the Phase IIa trial of drug candidate QGC001 – a group of independent experts tasked with […]